Stoke Therapeutics (STOK) Cash from Financing Activities (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Cash from Financing Activities of $84.3 million for Q1 2026, up 6037.34% year-over-year from $1.4 million in Q1 2025, and down 8.68% quarter-over-quarter from $92.3 million in Q4 2025.
Stoke Therapeutics (STOK) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at $84.3 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 6037.34% year-over-year to $84.3 million; the TTM figure through Mar 2026 stood at $180.3 million (up 37.93% YoY), while the FY2025 annual figure was $97.4 million, down 25.71% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $84.3 million, down from $92.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $120.6 million in Q2 2024, with the low at $43000.0 in Q4 2022.
- The 5-year median for Cash from Financing Activities is $3.1 million (2025), against an average of $24.2 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities soared 251254.17% in 2024, then tumbled 99.54% in 2025.
- Stoke Therapeutics' Cash from Financing Activities stood at $43000.0 in 2022, then surged by 16976.74% to $7.3 million in 2023, then slumped by 92.26% to $568000.0 in 2024, then surged by 16157.22% to $92.3 million in 2025, then declined by 8.68% to $84.3 million in 2026.
- Business Quant data shows STOK's Cash from Financing Activities at $84.3 million in Q1 2026, $92.3 million in Q4 2025, and $3.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 1.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.91 Mn |
| Jun 30, 2026 | 1.91 Mn |
| Mar 31, 2026 | 84.33 Mn |
| Mar 31, 2026 | 84.33 Mn |
| Dec 31, 2025 | 92.34 Mn |
| Dec 31, 2025 | 92.34 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | 554,000.00 |
| Jun 30, 2025 | 554,000.00 |
| Mar 31, 2025 | 1.37 Mn |
| Mar 31, 2025 | 1.37 Mn |
| Dec 31, 2024 | 568,000.00 |
| Dec 31, 2024 | 568,000.00 |
| Sep 30, 2024 | 8.16 Mn |
| Sep 30, 2024 | 8.16 Mn |
| Jun 30, 2024 | 120.65 Mn |
| Jun 30, 2024 | 120.65 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.72 Mn |